Patents for A61P 35 - Antineoplastic agents (221,099)
05/2007
05/30/2007CN1969824A Anticancer sustained release agent containing fluorouracil and synergist thereof
05/30/2007CN1969823A Sustained release agent containing fluorouracil and synergist thereof
05/30/2007CN1969821A Anticancer medicament and synergist simultaneously carrying anticancer sustained release agent
05/30/2007CN1969820A Anticancer pharmaceutical composition
05/30/2007CN1969819A Anticancer pharmaceutical composition
05/30/2007CN1969818A Anticancer sustained release injection containing epothilone derivatives
05/30/2007CN1969817A Anticancer composition
05/30/2007CN1969816A Anticancer sustained release agent containing epothilone
05/30/2007CN1969815A Sustained release agent of curcumin and preparation method thereof
05/30/2007CN1969814A Nasal administered preparation of melatonin
05/30/2007CN1318591C Immune tbid gene and its coded protein and application
05/30/2007CN1318590C Human protooncogene KG-20 and protein encoded therein
05/30/2007CN1318586C Method for the in vitro synthesis of short double stranded RNAs
05/30/2007CN1318450C Modified/chimeric super-antigens and their use
05/30/2007CN1318430C Rare-earth compounds and their preparing method and use in preparing tumour treating medicine
05/30/2007CN1318427C Compound of hydrogenised trichodermol, preparation process and application
05/30/2007CN1318426C Novel cantharidimide and norcantharidimide derivant and its application in medicine
05/30/2007CN1318422C Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
05/30/2007CN1318413C Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
05/30/2007CN1318411C Ketones compound of hydrogenized diasporangiumsp, preparation method and application
05/30/2007CN1318409C Oxy-and amino-substituted tetrahydrofurl derivatives with antitumour activity
05/30/2007CN1318408C Azo hetercyle beta-elemene derivative and its preparation method and uses
05/30/2007CN1318406C New barbituric acid derivatives, processes for their production and pharmaceutical agent containing same
05/30/2007CN1318405C Azo heterocycle beta-elemene piperazine alkyl derivative and its preparation and uses
05/30/2007CN1318404C Aryl ureas as kinase inhibitors
05/30/2007CN1318403C Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments
05/30/2007CN1318402C Pyrrolidine-2-carboxylic acid hydrozide derivatives for use as metalloprotease inhibitors
05/30/2007CN1318388C Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
05/30/2007CN1318103C Medical products comprising a haemocompatible coating, production and use thereof
05/30/2007CN1318102C Medical devices containing rapamycin analogs
05/30/2007CN1318092C Immunity treatment composition containing antibody-cytokine fusion protein mediated and angiogenesis inhibitor
05/30/2007CN1318091C Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases
05/30/2007CN1318086C Use of soluble CTLA4 molecule in preparation of medicine composition for treating rheumatic diseases
05/30/2007CN1318084C Neuroprotective peptides
05/30/2007CN1318073C Chinese medicine compound preparation for treating lung cancer
05/30/2007CN1318032C Ethinyl estradiol gas permeable absorbing paste
05/30/2007CN1318029C Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1, 2, 3-triazoles
05/30/2007CN1318028C Slow-releasing micro-balls of demethyl cantharidine, and its preparation method
05/30/2007CN1318016C New composition including a pigment assembly comprising a mica core
05/29/2007WO2006034832A2 Use of igfbp-2 in senescence diseases and for the maintenance of organ functions
05/29/2007US7225083 Determination antagonist, moderators; three-dimensional models
05/29/2007US7223858 Truncated aggrecanase molecules
05/29/2007US7223852 Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor family
05/29/2007US7223837 Anticancer prodrugs, enhance enzymatic activation rates
05/29/2007US7223835 Cyclic peptide mimetic for treating cancer; anticarcinogenic agents
05/29/2007US7223798 treating inflammatory or autoimmune disorders and pulmonary or respiratory tract inflammation
05/29/2007US7223784 Compounds for the modulation of the glycolysis enzyme and/or transaminase complex
05/29/2007US7223783 Indolinone derivatives
05/29/2007US7223781 Immunomoderators; autoimmune disease; drug, cosmetics; antiinflammatory agnets
05/29/2007US7223777 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
05/29/2007US7223772 Cyclooxygenase-2 inhibitors (COX-2); 4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide for example; fever, pain, inflammation, neurodegenerative disorders, oral diseases, influenza, arthritis, allergies
05/29/2007US7223763 Substituted sulfonamides and ureas useful for inhibiting kinase activity
05/29/2007US7223758 Such as (3S)-2-[3-[(phenylacetyl)amino]-1-oxopropyl]-N-[cyano(3-phenoxyphenyl)methyl]hexahydro-3-pyridazinecarboxamide; for treatment of osteoporosis, hypercalcaemia, osteoporosis, gingival disease, arthritis, Paget's disease, and bone cancer
05/29/2007US7223751 Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same
05/29/2007US7223745 Proteasome inhibitors and methods of using the same
05/29/2007US7223741 nucleic acids containing unmethylated cytosine-guanine (CpG) dinucleotides activate lymphocytes in a subject and redirect a subject's immune response from a Th2 to a Th1
05/29/2007US7223738 Inhibitors of Akt activity
05/29/2007US7223736 Composition for the prevention and treatment of cachexia
05/29/2007US7223731 Comprises use of thrombospondin biological fragments and domains to treat and prevent cell proliferation disorders; antitumor agents
05/29/2007US7223600 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination
05/29/2007US7223593 Anticancer agents; gene coding immunomoderator cytokine protein
05/29/2007US7223585 Viral purification methods
05/29/2007US7223542 Diagnosing cancer via determining concentration of marker polypeptides; genetic vaccines; antiproliferative/antitumor agents
05/29/2007US7223398 Population of conjugate molecules of an allergen and a polynucleotide comprising an immunostimulatory sequence; polynucleotide conjugated, or attached, to antigens
05/29/2007US7223397 Administering an agent which upregulates the expression of a cellular target; administering a dose of an immunotoxin directed against the upregulated cellular target
05/29/2007US7223394 Human antibodies that bind human TNFα
05/29/2007US7223393 Monoclonal antibodies for use in the prevention and treatment of cell proliferative and skin disorders; immunotherapy; antitumor agents
05/29/2007US7223389 Compositions and methods for treatment of cancer
05/29/2007US7223388 Reoviridae virus is conjugated to a hydroxylated hydrocarbon or a polycationic polymer to reduce the clearance and immunogenicity; antiproliferative disorders
05/29/2007CA2236998C Tissue-specific and target rna-specific ribozymes
05/29/2007CA2214565C New cryptophycins from synthesis
05/29/2007CA2190659C Taxoids, preparation and pharmaceutical compositions containing them
05/29/2007CA2168080C Process for the preparation of 1-(2'-deoxy-2',2'-difluoro- d-ribopentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro- beta-d-ribo-pentopyranose
05/24/2007WO2007059404A2 Duocarmycin derivatives as novel cytotoxic compounds and conjugates
05/24/2007WO2007059356A2 Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
05/24/2007WO2007059300A2 Anti-alk antagonist and agonist antibodies and uses thereof
05/24/2007WO2007059299A1 Aminopyrimidines useful as kinase inhibitors
05/24/2007WO2007059219A1 Azaindazoles useful as inhibitors of kinases
05/24/2007WO2007059155A1 Treatment of cancers having resistance to chemotherapeutic agents
05/24/2007WO2007059154A2 Treatment of cancers with acquired resistance to kit inhibitors
05/24/2007WO2007059118A1 Combretastatin derivatives and related therapeutic methods
05/24/2007WO2007059078A1 Treatment of multiple myeloma with dasatinib
05/24/2007WO2007058992A2 Mutations and polymorphisms of hdac6
05/24/2007WO2007058991A2 Mutations and polymorphisms of c-abl
05/24/2007WO2007058630A1 Novel bis(amino)-ortho-dicarbaborane cluster compounds
05/24/2007WO2007058628A1 Heteroalkyl linked pyrimidine derivatives
05/24/2007WO2007058627A1 Oxygen linked pyrimidine derivatives
05/24/2007WO2007058536A1 Pharmaceutical composition for treating or preventing ovarian cancer
05/24/2007WO2007058482A1 Novel inhibitors of protein kinase
05/24/2007WO2007058322A1 Basic group-containing compound and use thereof
05/24/2007WO2007058235A1 Fusion protein and use thereof for pharmaceutical purposes
05/24/2007WO2007058190A1 Controlled drug release composition and drug releasing medical device
05/24/2007WO2007057705A1 Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (pbr)
05/24/2007WO2007057687A1 Piperazine derivatives and their use in therapy
05/24/2007WO2007057617A1 Lectin-defencin chimeric protein
05/24/2007WO2007057457A2 Neuroendocrine tumor treatment using mtor inhibitors
05/24/2007WO2007057440A2 Improved methods of using phosphoantigen for the treatment of cancer
05/24/2007WO2007057431A1 New method for treating cancer based on the modulation of calcineurin
05/24/2007WO2007057399A2 Treatment of cancer with indole derivatives
05/24/2007WO2007057397A1 Treatment of cancer